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Background:Major orthopedic surgery, such as elective total hip replacement (eTHR)
and elective total knee replacement (eTKR), are associated with a higher risk of venous
thromboembolism (VTE) than other surgical procedures. Little is known, however,
about the cost-effectiveness of VTE prophylaxis strategies in people undergoing these
procedures.
Aim: The aim of this work was to assess the cost-effectiveness of these strategies
from the English National Health Service perspective to inform NICE guideline (NG89)
recommendations.
Materials andMethods: Cost-utility analysis, using decisionmodeling, was undertaken
to compare 15 VTE prophylaxis strategies for eTHR and 12 for eTKR, in addition to “no
prophylaxis” strategy. The analysis complied with the NICE Reference Case. Structure
and assumptions were agreed with the guideline committee. Incremental net monetary
benefit (INMB) was calculated, vs. the model comparator (LMWH+ antiembolism
stockings), at a threshold of £20,000/quality-adjusted life-year (QALY) gained. The model
was run probabilistically. Deterministic sensitivity analyses (SAs) were undertaken to
assess the robustness of the results.
Results: The most cost-effective strategies were LMWH for 10 days followed by
aspirin for 28 days (INMB = £530 [95% CI: -£784 to £1,103], probability of being most
cost-effective = 72%) for eTHR, and foot pump (INMB = £353 [95% CI: -£101 to
£665]; probability of being most cost-effective= 18%) for eTKR. There was considerable
uncertainty regarding the cost-effectiveness ranking in the eTKR analysis. The results
were robust to change in all SAs.
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Conclusions: For eTHR, LMWH (standard dose) for 10 days followed by aspirin for 28
days is the most cost-effective VTE prophylaxis strategy. For eTKR, the results are highly
uncertain but foot pump appeared to be the most cost-effective strategy, followed closely
by aspirin (low dose). Future research should focus on assessing cost-effectiveness of
VTE prophylaxis in the eTKR population.
Keywords: venous thromboembolism (VTE) prophylaxis, pharmacoeconomics, cost utility analysis (CUA), total
knee replacement (TKR), total hip replacement (THR), direct-acting oral anticoagulants, NICE guideline
INTRODUCTION
Hospital-acquired venous thromboembolism (VTE), also
referred to as hospital-acquired thrombosis (HAT), represents
a major patient safety concern (Hauck et al., 2017). The
Department of Health, in England, defines it as “any episode
of VTE arising in the 90 days following admission to hospital”
(Arya et al., 2010). VTE can occur in the deep veins of either the
legs or pelvis [a deep vein thrombosis (DVT)] or can present as
a pulmonary embolism (PE) which can be fatal (Hunt, 2016).
Treatment of non-fatal HAT and related long-term morbidities
is associated with considerable cost (Barco et al., 2016). In the
USA, the 5-year costs were predicted to be 1.5-fold higher for
patients with HAT following major surgery ($55,956) than for
hospitalized controls ($32,718; P < 0.001). Litigation costs and
financial penalties on hospitals as a result of failure to prevent
HAT have added to this huge cost impact (Cohoon et al., 2015;
White et al., 2015).
The incidence of HAT is estimated to represent around
50–60% of all VTE seen globally (ISTH Steering Committee
for World Thrombosis Day, 2014). It was the leading cause
of disability-adjusted life-years in low- and middle-income
countries, and the second most common cause in high-income
countries (ISTH Steering Committee for World Thrombosis
Day, 2014). The National VTE prevention program in England
mandates that VTE risk assessment should be undertaken
upon admission to hospital and thromboprophylaxis started
soon after, in line with the recommendations of the National
Institute for Health and Care Excellence (NICE; National
Clinical Guideline Centre, 2010). This has shown positive
outcomes in terms of reducing the incidence of HAT (Roberts
et al., 2013). Thromboprophylaxis includes mechanical (such as
anti-embolism stockings [AES], foot impulse and intermittent
pneumatic compression devices [IPCD]) and pharmacological
interventions (such as low molecular weight heparins [LMWHs],
fondaparinux, direct-acting oral anticoagulants [DOACs] and
low-dose aspirin) which can be used alone or in combination.
Abbreviations: AES, anti-embolism stockings; CRNMB, clinically-relevant non-
major bleeding; CTEPH, chronic thromboembolic pulmonary hypertension;
CUA, cost utility analysis; DVT, deep vein thrombosis; eTHR, elective total
hip replacement; eTKR, elective total knee replacement; HIT, Heparin-induced
thrombocytopaenia; ICER, incremental cost effectiveness ratio; LMWH, low
molecular weight heparin; MB, major bleeding; NICE, National Institute for
Health and Care Excellence; NJR, National Joint Registry; NMA, network meta-
analysis; PE, pulmonary embolism; PTS, post thrombotic syndrome; QALYs,
quality adjusted life years; Std, standard; VTE, venous thromboembolism.
According to the recommendations of published clinical
guidelines, the need for and choice of a thromboprophylaxis
strategy should be based on the population and the outcome of
VTE risk assessment (Gould et al., 2012; National Institute for
Health and Care Excellence, 2018).
Major orthopedic surgery, such as elective total hip
replacement (eTHR) and elective total knee replacement
(eTKR), are associated with a higher risk of VTE than other
surgical populations (National Clinical Guideline Centre,
2010). However, the use of pharmacological agents for
thromboprophylaxis, particularly the DOACs, should be
balanced against the increase in risk of post-operative bleeding
as a result of anticoagulation (Dahl et al., 2010). Additionally,
the routine use of VTE prophylaxis in these populations has a
considerable cost impact for the units delivering care (Board NE,
2017). According to the 14th report of the National Joint Registry
(NJR) for 2017; there were 101,651 hip replacement operations
and 108,713 knee replacement operations in England, Wales
and Northern Ireland (Board NE, 2017). The large majority
of these operations are elective primary lower limb total joint
replacement procedures. The use and choice of VTE prophylaxis
in these high-volume procedures should ideally represent value
for money and justify the use of the scarce healthcare resources.
A literature review of published economic evaluations of VTE
prophylaxis in eTHR and eTKR populations, completed during
the development of NICE guideline NG 89 (National Institute
for Health and Care Excellence, 2018), identified 32 [(Davies
et al., 2000; Dahl and Pleil, 2003; Gordois et al., 2003; Lundkvist
et al., 2003; Annemans et al., 2004; Dranitsaris et al., 2004,
2009; Haentjens et al., 2004; Reeves et al., 2004; Bjorvatn and
Kristiansen, 2005; Bischof et al., 2006; National Colloborating
Centre for Acute Care, 2007; National Institute for Health and
Clinical Excellence, 2008, 2009, 2012; McCullagh et al., 2009,
2012; Stevenson et al., 2009; Wolowacz et al., 2009, 2010; Capri
et al., 2010; Diamantopoulos et al., 2010; National Clinical
Guideline Centre, 2010; Braidy et al., 2011; Riemsma et al., 2011;
Ryttberg et al., 2011; McDonald et al., 2012; Migliaccio-Walle
et al., 2012; Postma et al., 2012; Zindel et al., 2012; Hamidi et al.,
2013; Revankar et al., 2013; Gomez-Outes et al., 2014; Wade
et al., 2015; Sterne et al., 2016)] and 30 studies (Gordois et al.,
2003; Lundkvist et al., 2003; Annemans et al., 2004; Dranitsaris
et al., 2004, 2009; Haentjens et al., 2004; Reeves et al., 2004;
Bjorvatn and Kristiansen, 2005; Bischof et al., 2006; National
Colloborating Centre for Acute Care, 2007; National Institute
for Health and Clinical Excellence, 2008, 2009, 2012; Stevenson
et al., 2009; Wolowacz et al., 2009, 2010; Capri et al., 2010;
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Diamantopoulos et al., 2010; National Clinical Guideline Centre,
2010; Braidy et al., 2011; Riemsma et al., 2011; Ryttberg et al.,
2011; McCullagh et al., 2012; McDonald et al., 2012; Migliaccio-
Walle et al., 2012; Postma et al., 2012; Zindel et al., 2012;
Hamidi et al., 2013; Revankar et al., 2013; Gomez-Outes et al.,
2014; Wade et al., 2015; Sterne et al., 2016) respectively. The
interventions compared and the most cost-effective prophylaxis
strategy varied among these studies. Hence; this economic
analysis was undertaken to assess the cost effectiveness of
thromboprophylaxis strategies for eTHR and eTKR populations
in English National Health Service (NHS) hospitals to inform
the recommendations of the updated NICE guideline (NG89)
(National Institute for Health and Care Excellence, 2018). This
analysis takes into account the risks, benefits and costs of all
the currently available thromboprophylaxis options in England
and addresses the limitations of previously published models and
economic analyses in this area.
MATERIALS AND METHODS
A cost-utility analysis (CUA) was conducted from the perspective
of the NHS and Personal Social Services (PSS), with quality-
adjusted life-years (QALYs) and costs as the main outcome
measures. The analysis complied with the NICE Reference Case,
which is a set of methodological standards specified by NICE
including using lifetime time horizon and applying discounting
at a 3.5% discount rate for costs and outcomes accrued beyond
the first year (National Institute for Health and Care Excellence,
2014). The reporting of the study follows the ConsolidatedHealth
Economic Evaluation Reporting Standards (CHEERS) statement
(Husereau et al., 2013). No ethics approval was required for this
study.
Comparators
Interventions included in the model are outlined in Table 1,
below, for eTHR and eTKR populations. These were decided
in discussion with the clinical experts and patient members of
the guideline committee to reflect currently used prophylaxis
strategies in the UK. They were identified through a systematic
review (SR) of published randomized controlled trials (RCTs)
and were included in network meta-analyses (NMAs) of
the main outcomes of interest. The detail of the SR and
NMAs is reported in appendix M of the full NICE guideline
(NG89) (National Institute for Health and Care Excellence,
2018).
The systematic review was very comprehensive, including all
thromboprophylaxis strategies that were assessed in randomized
controlled trials including those that do not represent current
practice in the UK (e.g., LMWH in doses of 60mg per day and
aspirin in doses up to 300mg daily). This was decided to increase
the power of the NMAs. For the economic evaluation, however,
only interventions that were largely in line with current practice
in the UK and, thus, are considered relevant to decision making
were included.
For strategies that included LMWH, only those that included
prophylactic rather than treatment doses were included. The
range of prophylactic LMWH doses was based on published
guidance and expert input from the pharmacist member of
the committee and was confirmed by the other committee
members. The term “standard dose” was used to describe
LMWH prophylactic doses. Additionally, the duration of use was
differentiated into either standard (10–14 days) or extended (28–
35 days). It was assumed that all LMWHs used are the originator
rather than biosimilar options.
For strategies including aspirin, daily doses of up to 300mg
of aspirin were included in the NMA. For the economic
evaluation, we modeled these as including low-dose aspirin
(75–150mg) administered for either standard (10 to 14 days)
or extended duration (28–35 days). Complete details of the
strategies compared in the model are available in Appendix P of
NG89 and are summarized here in Table 1.
Model Description
A decision analytic model was developed and run separately for
each of the two populations to reflect the difference in baseline
characteristics, VTE and bleeding risks and prophylaxis duration.
However, the structure of the model was the same for both
populations.
The model consisted of a simple decision tree covering the
acute phase from admission up to 90 days post-operatively, to
cover the period included in the definition of hospital-acquired
VTE, followed by a Markov model for the remaining model time
horizon (lifetime in the base case). Markov models use disease
states to represent all possible consequences of an intervention of
interest.
The structure of the decision tree is presented in Figure 1A.
It included the following events: DVT (symptomatic proximal,
symptomatic distal, asymptomatic proximal, and asymptomatic
distal), non-fatal PE, fatal PE, surgical site bleeding (SSB), non-
surgical site bleeding (gastrointestinal (GI) bleeding, intracranial
hemorrhage (ICH)/haemorrhagic stroke, other major bleeding),
fatal major bleeding, clinically-relevant non-major bleeding
(CRNMB), and heparin-induced thrombocytopaenia (HIT).
Major bleeding (MB) events in the model could be at the surgical
site; in which case it would result in return to theater, or at
another site. MB occurring in the GI tract was assumed to
require intervention in 13% of cases (National Clinical Guideline
Centre, 2010). ICH/haemorrhagic stroke was assumed to lead to
permanent disability.
Individuals who develop CRNMB were assumed to either be
medically treated or develop a wound haematoma that could lead
to a surgical site infection (SSI). SSIs could either be medically
treated or require surgical intervention; which could be either
a return to theater or a revision arthroplasty, in a ratio of 1:1.
Individuals developing HIT were assumed to be treated with a
therapeutic dose of fondaparinux. Outcomes included successful
treatment, new thrombosis (assumed to be either symptomatic
proximal DVT or PE in a ratio of 1:1), major bleeding or
death.
The structure of the Markov cohort model is illustrated
in Figure 1B. Individuals enter the model in one of the
following states: Well, post-symptomatic proximal DVT, post-
symptomatic distal DVT, post-asymptomatic proximal DVT,
post-asymptomatic distal DVT, post-PE, amputated post-HIT,
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TABLE 1 | Interventions included in the model by population.
Strategy Duration (a)
Elective total hip replacement (eTHR)
None No prophylaxis Not applicable
Mechanical only AES (above-knee)
AES (length unspecified)
7 days
10 days
IPCD (length unspecified) 8 days
Foot pump 7 days
Foot pump
+ AES
7 days
Pharmacological only LMWH [standard dose (b); standard duration] 14 days
LMWH [standard dose (b); extended duration] 33 days
Dabigatran (c) 32 days
Rivaroxaban (d) 35 days
Apixaban (e) 32 days
Aspirin (f; low dose, standard duration) 7 days
LMWH [standard dose(b), standard duration] followed by aspirin (low dose, extended
duration)
10 days (LMWH) followed
by 28 days (aspirin)
Combination (Pharmacological + mechanical) LMWH [standard dose (b); standard duration] + AES 14 days (LMWH) +10 days
(AES) +
LMWH [standard dose (b); extended duration] + AES 33 days (LMWH) + 10 days
(AES)
Fondaparinux (g) + AES 8 days (fondaparinux) 10
days (AES)
Elective total knee replacement (eTKR)
None No prophylaxis Not applicable
Mechanical only AES (length unspecified) 11 days
IPCD (length unspecified) 6 days
Foot pump 4 days
Foot pump
+ AES
4 days
+ 11 days
Pharmacological only LMWH [standard dose (b); standard duration] 10 days
LMWH [standard dose (b); extended duration] 30 days
Dabigatran (h) 11 days
Rivaroxaban (d) 13 days
Apixaban (e) 12 days
Aspirin (f; low dose, standard duration) 14 days
Combination (Pharmacological + mechanical) LMWH [standard dose (b); standard duration] + AES 10 days
Fondaparinux (g) + AES 11 days
AES, anti-embolism stockings; IPCD, intermittent pneumatic compressions device; LMWH, low molecular weight heparin.
aAverage dose and duration based on the randomized controlled trials identified in the systematic review and network meta-analysis.
bLMWH standard prophylactic dose included enoxaparin sodium 40mg once daily, Dalteparin sodium 5,000 iu once daily and tinzaparin sodium 4,500 iu once daily.
cDabigatran dose for THR: For Adult 18–74 years, 110mg, to be taken 1–4 h after surgery, followed by 220mg once daily. For Adult 75 years and over: 75mg, to be taken 1–4 h after
surgery, followed by 150mg once daily to be taken 12–24 h after initial dose.
dRivaroxaban dose: 10mg once daily.
eapixaban dose: 2.5mg twice daily.
faspirin dose 75 – 150mg once daily.
g fondaparinux dose: 2.5mg once daily.
hdabigatran dose for TKR: For Adult 18–74 years: 110mg, to be taken 1–4 h after surgery, followed by 150mg once daily, to be taken 12–24 h after initial dose. For Adult 75 years and
over: 75mg, to be taken 1–4 h after surgery, followed by 150mg once daily, to be taken 12–24 h after initial dose.
disabled post-stroke, post-revision for infection. In the first
two years, individuals in a post-VTE state can develop post-
thrombotic syndrome (PTS). Those in the post-PE state can
also develop chronic thromboembolic pulmonary hypertension
(CTEPH). The first year after the diagnosis of each of PTS
or CTEPH is represented in the model by a distinct “tunnel”
state, where individuals stay for one cycle only. Additionally,
the second year after a recurrent/resistant CTEPH is represented
by a “tunnel” state to account for the difference in costs
from a chronic CTEPH state. Transitioning to death is
allowed from any state in the model, to represent all-cause
mortality.
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Panel 1 | Main assumptions used in the model
• Asymptomatic DVT is not diagnosed in practice and will not be treated or
lead to extra costs or loss in quality of life in the short term.
• Only one symptomatic event is allowed in the model in the first 90 days;
given that the treatment course for these events is 3 months long and once
an event is diagnosed; the individual would receive treatments and would no
longer be considered to be receiving primary prophylaxis.
• Those who develop symptomatic proximal DVT or PE will receive
treatment. The treatment used was assumed to be either a direct
oral anticoagulant (rivaroxaban or apixaban) or LMWH followed by vit-K
antagonist (warfarin) in a ratio of 50% each. Dabigatran and edoxaban were
excluded due to the initial 5-day dosing with LMWH following VTE diagnosis.
• It was assumed the treatment of VTE events is 100% effective, regardless
of which VTE treatment regimen is used and no allowance for recurrence
was made in the model. This was decided based on discussions with the
committee where it was decided that the rate of recurrence after a provoked
VTE is much lower compared to unprovoked VTE event. It was also felt that
the prevention of a provoked event will not necessarily lead to prevention of
recurrence which might be a result of a previous undiagnosed VTE event or
an inherent susceptibility, including thrombophilia.
• The relative efficacy of the included comparators on the model outcomes
was applied during the acute phase of the model, after which progression
through the model was treatment-independent.
A number of assumptions were made when developing the
model. These were discussed in detail with and agreed by the
guideline committee (see Panel 1).
Simulation Cohort
The cohort characteristics for each population were based on data
from the National Joint Registry (NJR) 13th annual report (Board
NE, 2017), which were collected up to December 2015. These are
presented in Table 2.
Baseline Risks
Baseline risks of VTE andmajor bleeding were based on two large
observational cohort studies that used the NJR data (Jameson
et al., 2011, 2012). In both, data for England and Wales, linked
to an administrative database of hospital admissions in the
English National Health Service (Hospital Episode Statistics
[HES] database), were analyzed. The two studies only reported
symptomatic DVT events. Hence, we used the asymptomatic-to-
symptomatic DVT as reported in Quinlan (2007), to calculate
the number of asymptomatic DVT events that would have been
observed in these populations (see Table 2).
Relative Treatment Effects
DVT and PE
The risk ratios (RRs) for each prophylaxis strategy compared
to LMWH (std/std) + AES were based on systematic reviews
and network meta-analyses (NMAs) of the outcomes: all DVT
(symptomatic and asymptomatic) and non-fatal PE. The detail of
these systematic reviews and NMAs are reported in appendix M
of the full guideline (NG89) (National Institute for Health and
Care Excellence, 2018). The absolute risks for each prophylaxis
strategy were calculated by multiplying the RRs obtained from
the NMA by the baseline risk of each event. These are presented
in Table 3. Where an intervention had data available for DVT
or PE only, we assumed proportionality of effect on these
events. This assumption has been tested in 11 one-way sensitivity
analyses (SAs).
Bleeding Events
The relative efficacy of the included interventions compared to
LMWH (std,std)+AES was calculated from systematic review
and NMA of non-fatal MB reported in appendix M of the full
NICE guideline (NG89; National Institute for Health and Care
Excellence, 2018). In the model, we use these ORs and the
baseline risk on LMWH (std,std)+AES to calculate the absolute
risk of each MB event in the model. These ORs were also used
to calculate the absolute risk of CRNMB when an intervention
did not have trial data for this outcome. Wound haematoma and
subsequent SSI were modeled as consequences of CRNMB, based
on epidemiological data.
In the MB NMA, we assumed that the major bleeding
rate for mechanical only strategies is the same as for the no
prophylaxis strategy and these were treated as one intervention
(National Institute for Health and Care Excellence, 2018). This
was considered reasonable on biological grounds. No other
complications from mechanical prophylaxis were included in
the model. However, given the established evidence that some
patients find stockings uncomfortable (Wade et al., 2015),
causing patients to wear them incorrectly (especially thigh-length
stockings), we included the cost of nurse time required for
checking that mechanical prophylaxis is fitted correctly. The
absolute risks of the bleeding events for each prophylaxis strategy
are presented in Table 3.
Utilities
A SR was conducted to identify utility inputs to use in the model.
Additionally, we examined the sources used in the published
economic evaluations and existing NICE Technology Appraisals
(TAs) (National Institute for Health and Clinical Excellence,
2009, 2012; National Clinical Guideline Centre, 2010; National
Institute for Health and Care Excellence, 2015).
For baseline utility values, we used EQ-5D-3L index values
reported in the UK 2014-2015 PROMS programme (NHSDigital,
2016). The PROMS programme collects EQ-5D-3L data pre- and
6 months post-operatively for eTHR and eTKR patients. The
post-operative EQ-5D-3L index values reported in the PROMS
data represent the utility at 6–12 months. We assumed that this
value would be reached at the mid-point (9 months). We also
assumed a linear increase from the pre-operative utility over the
6 months (180 days) to calculate the utility score at 90 days (the
point of entry to the Markov model).
Event-specific (Dis) utilities were applied as event-based after
which the individual’s QoL recovers and continues on the post-
operative linear improvement trajectory to achieve the utility
value at 90-days post-operatively. For the purpose of calculating
QALYs, it was assumed that DVT and any adverse events take
place on day 7 while PE events take place on day 21. This was
based on committee estimates. Data from Warwick 2007 were
used in sensitivity analysis (Warwick et al., 2007). All (dis)utility
values are listed in Tables 4, 5.
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FIGURE 1 | (A) Model structure up to 90 days post-operatively (Decision tree part). (B) Model structure after 90 days post-operatively (Markov model part).
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TABLE 2 | Summary of base-case model inputs and their sources.
Input Data Source
COHORT SETTINGS
Start age (years) eTHR: 68.7 (SD = 11.32)
eTKR: 69.3 (SD = 9.58)
National Joint Registry Annual Report 2016 (Board NE, 2017)
Male eTHR: 40%
eTKR: 44%
National Joint Registry Annual Report 2016 (Board NE, 2017)
BMI (kg/m2) eTHR: 28.7
eTKR: 30.9
National Joint Registry Annual Report 2016 (Board NE, 2017)
BASELINE RISKS–e THR
DVT (symptomatic and asymptomatic) 5.54% Calculated based on (Jameson et al., 2011) and (Quinlan, 2007)
Symptomatic DVT 0.94% (Jameson et al., 2011)
Proportion of symptomatic DVTs that are proximal 83.3% (Revankar et al., 2013) based on data from ADVANCE trials
Asymptomatic DVT 4.6% Calculated based on (Jameson et al., 2011) and (Quinlan, 2007)
Proportion of asymptomatic DVTs that are proximal 26.2% (Revankar et al., 2013) based on data from ADVANCE trials
Non-fatal PE 0.68% (Jameson et al., 2011)
Mortality from PE 17% (1/6) Randomized controlled trials in our systematic review
Major bleeding at the surgical site 2.29% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
GI and cerebrospinal bleeding 0.72% (Jameson et al., 2011)
Other major bleeding 0.2% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
Clinically-relevant non-major bleeding (CRNMB) 2.95% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
Wound haematoma as percentage of CRNMB 22.73% (5/22) Calculated from the LMWH randomized controlled trials in our systematic review
Heparin-induced thrombocytopenia (HIT) 0.17% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
BASELINE RISK - eTKR
DVT (symptomatic and asymptomatic) 14% Calculated based on (Jameson et al., 2012) and (Quinlan, 2007)
Symptomatic DVT 0.63% (Jameson et al., 2012)
Proportion of symptomatic DVTs that are proximal 20% (Revankar et al., 2013) based on data from ADVANCE trials
Asymptomatic DVT 13.37% Calculated based on (Jameson et al., 2012) and (Quinlan, 2007)
Proportion of asymptomatic DVTs that are proximal 8.8% (Revankar et al., 2013) based on data from ADVANCE trials
Non-fatal PE 0.45% (Jameson et al., 2012)
Mortality from PE 17% assumed equal to eTHR as there were no events in the single trial of LMWH (standard
dose, standard duration)+ AES
Major bleeding at the surgical site 0.64% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
GI and cerebrospinal bleeding 0.39% (Jameson et al., 2012)
Other major bleeding 0.2% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
CRNMB 4.15% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
Wound haematoma as percentage of CRNMB 18.97% (11/58) Calculated from the LMWH randomized controlled trials in our systematic review
HIT 0.92% Single-arm meta-analysis of the LMWH (standard dose, standard duration)
randomized controlled trials in our systematic review
OTHER PARAMETERS
Proportion requiring return to theater after surgical
site major bleeding
100% Standard definition of major bleeding and expert opinion
Proportion requiring intervention after GI bleeding 13% CG92 (National Clinical Guideline Centre, 2010)
Surgical site infection due to haematoma 25.77% (25/97) Wang 2014 (Wang et al., 2014)
Probability of revision/return to theater due to
infection
44% (11/25) Wang 2014 (Wang et al., 2014)
LONG TERM EVENTS
2-year incidence of PTS after:
Symptomatic proximal DVT 40% (Kahn et al., 2016) and committee Expert opinion
(Continued)
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TABLE 2 | Continued
Input Data Source
Symptomatic distal DVT 10% (Heit et al., 2001; Botteman et al., 2002) and committee opinion
Asymptomatic proximal DVT 15% (Wille-Jørgensen et al., 2005)
Asymptomatic distal DVT 3.75% (Heit et al., 2001; Botteman et al., 2002)
Non-fatal PE 15% Committee expert opinion
Proportion of PTS that is severe 23% [(Wolowacz et al., 2009); average from 8 incidence studies]
2-year incidence of CTEPH after non-fatal PE 3.2% (95% CI: 1.5%−3.1%) [(Ende-Verhaar et al., 2017); systematic review of incidence studies]
CTEPH mortality 20% CG92 (National Clinical Guideline Centre, 2010)
COSTS (£)
Symptomatic proximal DVT eTHR: £457
eTKR: £457
NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Symptomatic distal DVT eTHR: £295
eTKR: £295
NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Non-fatal PE eTHR: £991
eTKR: £992
NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Return to theater for surgical site bleeding eTHR: £6,278
eTKR: £6,177
NHS Schedule for Reference Costs 2015–2016 [(Department of Health, 2016); unit
cost for primary eTHR]
NHS Schedule for Reference Costs 2015–2016 [(Department of Health, 2016); unit
cost for primary eTKR]
GI bleeding with intervention £2,409 NHS Schedule for Reference Costs 2015–2016 (Department of Health, 2016)
GI bleeding without intervention £855 NHS Schedule for Reference Costs 2015–2016 (Department of Health, 2016)
Haemorrhagic stroke
Acute event-admission £4,354 Weighted Cost of non-elective long stay admission for stroke with CC score 0-3 to
16+. HRG codes AA35A to AA35F.NHS Schedule for Reference Costs 2015–2016
(Department of Health, 2016)
Acute event- other costs for the first 90 days £3,255 Three month costs calculated based Weighted average cost of the cost of stroke
dependent state and independent state in year 1 from CG144 [VTE management and
thrombophilia testing] less the cost of the acute stroke admission (National Clinical
Guideline Centre, 2012a) Costs inflated to 2015–2016.
Year 1–dependent state £29,776 CG144 [VTE management and thrombophilia testing; (National Clinical Guideline
Centre, 2012a)] Costs inflated to 2015–2016
Year 1–independent state £4,971 CG144 [VTE management and thrombophilia testing; (National Clinical Guideline
Centre, 2012a)] Costs inflated to 2015–2016
Year 2+ – dependent state £15,108 CG144 [VTE management and thrombophilia testing; (National Clinical Guideline
Centre, 2012a)] Costs inflated to 2015–2016
Year 2+ – independent state £1,172 CG144 [VTE management and thrombophilia testing; (National Clinical Guideline
Centre, 2012a)] Costs inflated to 2015–2016
CRNMB (post-discharge) £242 Committee expert opinion (2 outpatient visits)
Surgical site infection- medically treated £3,696 NHS Schedule for Reference Costs 2015–2016
Revision surgery for infected joint eTHR: £19,514 eTKR:
£19,203
Kallala 2015 and NHS Schedule for Reference Costs 2015–2016
HIT £463 NHS Schedule for Reference Costs 2015–2016 (Department of Health, 2016)
Amputation after HIT:
acute event £10,300 CG 147 [Lower Limb Peripheral Arterial Disease; (National Clinical Guideline Centre,
2012b)] adjusted for inflation to 2015–2016 values
Year 1 £31,259 CG 147 [Lower Limb Peripheral Arterial Disease–(National Clinical Guideline Centre,
2012b)] adjusted for inflation to 2015–2016 values
Year 2+ £25,987 CG 147 [Lower Limb Peripheral Arterial Disease; (National Clinical Guideline Centre,
2012b)] adjusted for inflation to 2015–2016 values
PTS
Mild/Moderate -Year 1 £841 Caprini 2003 (Caprini et al., 2003) converted to 2000 GBP OECD PPP conversion
and inflated to 2015–2016 values
(Continued)
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TABLE 2 | Continued
Input Data Source
Mild/Moderate -Year 2+ £342 Caprini 2003 converted to 2000 GBP OECD PPP; (Organisation for Economic
Co-operation Development (OECD), 2012) conversion factor and inflated to
2015–2016 values
Severe -Year 1 £3,824 Caprini 2003 converted to 2000 GBP OECD PPP conversion; (Organisation for
Economic Co-operation Development (OECD), 2012) and inflated to 2015–2016
values
Severe -Year 2+ £1,680 Caprini 2003 converted to 2000 GBP OECD PPP conversion; (Organisation for
Economic Co-operation Development (OECD), 2012) and inflated to 2015–2016
values
CTEPH
Operable-Y1 £28,671 NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Recurrent/Resistant- Year 1 £29,470 NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Inoperable-Year 1 £9,677 NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Recurrent/resistant- Year 2 £21,845 NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Chronic-Year 2+ £13,967 NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
Treated CTEPH £147 NG89 (Venous thromboembolism in over 16s: reducing the risk of hospital-acquired
deep vein thrombosis or pulmonary embolism), Appendix P (National Institute for
Health and Care Excellence, 2018)
BMI, body mass index; CRNMB, clinically-relevant non-major bleeding; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; eTHR, elective total hip
replacement; eTKR, elective total knee replacement; GI, gastrointestinal; HIT, Heparin-induced thrombocytopenia; LMWH, low molecular weight heparin; PE, pulmonary embolism; PTS,
post-thrombotic syndrome.
Resource Use and Costs
Only direct medical costs calculated from the perspective of
the English NHS were included in the analysis. These included
interventions’ costs and costs of model events occurring in the
acute and long-term phase of the model.
Intervention Costs
Prophylaxis costs were calculated based on the dose and duration
used the in RCTs of each of its components (pharmacological
and/or mechanical). A sensitivity analysis using the licensed
doses and durations of pharmacological prophylaxis instead was
also conducted. The administration and monitoring costs were
included, where required. Intervention costs are presented in
Table 6.
Event Costs
We calculated the costs of diagnosing and treating
the model events. Resources required were identified
through discussions with the committee members and
examining previously published models, NICE Technology
Appraisals (TAs) and clinical guidelines. These resources
were then identified and valued according to standard
methods including micro-costing using bottom-up and
top-down approaches, as required (National Institute
for Health and Care Excellence, 2014). The resources
considered were those of diagnostic tests, drug treatments,
staff time, primary care, outpatient, and emergency
department visits, ICU admissions, ambulance transfer and
re-operation.
The costs of diagnosing, short and long term management of
the following events were included: symptomatic DVT, PE, MB
(gastrointestinal hemorrhage, surgical site bleeding, intracranial
hemorrhage (stroke), bleeding at any other site), CRNMB, SSI,
HIT, amputation as a result of HIT, CTEPH, severe and mild to
moderate PTS and post-stroke disability.
National sources of unit costs in the UK were used
including the Drug Tariff, British National Formulary (BNF),
NHS Supply Chain Catalog and NHS Schedule for Reference
Costs (Department of Health, 2015; NHS Business Services
Authority, 2015a,b; Curtis and Burns, 2016; Joint Formulary
Committee, 2016). The price year was 2016. Any costs
from earlier years were adjusted for inflation using the
Hospital and Community Health Services Pay and Prices Index
(Curtis and Burns, 2016). Costs based on published literature
from other countries were converted to 2016 GBP using
Organization for Economic Co-operation and Development
(OECD) purchasing power parity (PPP) calculator (Organisation
for Economic Co-operation Development (OECD), 2012).
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TABLE 3 | Absolute risk (%) of model events.
Strategy DVT (symptomatic and
asymptomatic) (95% CrI)
Non-fatal PE (95% CrI) GI bleeding
+ ICH
SSB Other major
bleeding
CRNMB
eTHR
LMWH (std,std) + AES 5.54%
(%5.39 to %5.70)
0.68%
(%0.63 to %0.74)
0.72% 0.94% 0.30% 3.04%
LMWH (std,extd)+ AEs 4.03%
(%0.53 to %14.34)
0.15%
(%0.00 to %0.94)
0.77% 0.70% 0.23% 3.04%
Fondaparinux+ AES 3.25%
(%0.46 to %11.43)
1.15%
(%0.09 to %5.12)
1.40% 1.57% 0.51% 4.98%
Foot pump + AES 14.66%
(%1.99 to %46.06)
1.48% (b) 0.34% 0.36% 0.12% 1.18%
IPCD 33.06%
(%5.56 to %76.99)
5.28%
(%0.15 to %31.35)
0.34% 0.36% 0.12% 1.18%
AES (above knee) 8.30%
(%0.87 to %48.85)
10.21%
(%0.00 to %88.30)
0.34% 0.36% 0.12% 1.18%
Foot pump 28.01%
(%2.41 to %78.81)
21.94%
(%0.11 to %98.05)
0.34% 0.36% 0.12% 1.18%
AES 12.05%
(%4.35 to %25.55)
1.18%
(%0.08 to %5.46)
0.34% 0.36% 0.12% 1.18%
LMWH (std,std) 20.30%
(%3.41 to %56.46)
2.47%
(%0.18 to %12.53)
0.72% 0.94% 0.30% 3.04%
LMWH (std,extd) 9.76%
(%0.97 to %36.66)
0.45%
(%0.00 to %3.19)
0.77% 0.70% 0.23% 3.04%
Aspirin (std duration) 26.26%
(%1.56 to %80.91)
36.63%
(%0.35 to %99.62)
0.79% (c) 1.03% 0.33% 3.29%
LMWH (std, std) + Aspirin
(extd duration)
0.05%(a) 0.11%
(%0.00 to %0.77)
0.80% 0.10% 0.03% 1.64%
Dabigatran 18.91%
(%2.05 to %60.30)
3.56%
(%0.13 to %20.41)
1.19% 1.34% 0.43% 3.48%
Apixaban 9.81%
(%0.55 to %43.30)
2.01%
(%0.05 to %12.24)
1.17% 1.16% 0.37% 2.75%
Rivaroxaban 4.00%
(%0.27 to %18.33)
1.20%
(%0.01 to %7.82)
0.95% 0.99% 0.32% 3.68%
No prophylaxis 40.42%
(%9.59 to %81.09)
8.80%
(%0.83 to %37.52)
0.34% 0.36% 0.12% 1.18%
eTKR
LMWH (std,std) + AES 14.00%
(%13.81 to %14.20)
0.45%
(%0.41 to %0.49)
0.39% 0.94% 0.21% 4.89%
Fondaparinux+ AES 12.51%
(%3.76 to %27.50)
0.36% (d) 4.20% 5.85% 1.34% 25.11%
Foot pump + AES 18.96%
(%9.45 to %33.25)
0.58% (d) 0.36% 0.88% 0.19% 4.58%
IPCD 21.23%
(%7.04 to %42.74)
1.92%
(%0.00 to %18.60)
0.36% 0.88% 0.19% 4.58%
Foot pump 8.38%
(%1.12 to %26.89)
0.20% (d) 0.36% 0.88% 0.19% 4.58%
AES 29.97%
(%15.13 to %48.19)
2.48%
(%0.007 to %20.33)
0.36% 0.88% 0.19% 4.58%
LMWH (std,std) 9.22%
(%2.98 to %20.08)
1.94%
(%0.00 to %19.44)
0.39% 0.94% 0.21% 4.89%
LMWH (std,extd) 7.83%
(%1.80 to %20.51)
0.87%
(%0.000 to %6.25)
0.43% 0.14% 0.03% 6.77%
Aspirin 15.28%
(%3.64 to %37.46)
0.43% (d) 0.38% (e) 0.93% 0.21% 4.84%
Dabigatran 9.10%
(%2.78 to %20.49)
5.06%
(%0.00 to %60.15)
0.44% 0.95% 0.21% 5.46%
(Continued)
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TABLE 3 | Continued
Strategy DVT (symptomatic and
asymptomatic) (95% CrI)
Non-fatal PE (95% CrI) GI bleeding
+ ICH
SSB Other major
bleeding
CRNMB
Apixaban 5.31%
(%1.54 to %12.44)
4.35%
(%0.000 to %49.77)
0.34% 0.69% 0.15% 3.78%
Rivaroxaban 4.32%
(%1.17 to %10.42)
1.45%
(%0.00 to %13.84)
0.64% 1.33% 0.29% 5.83%
No prophylaxis 34.21%
(%13.98 to %58.93)
4.47%
(%0.002 to %46.25)
0.42% 0.88% 0.19% 4.58%
AES, anti-embolism stockings; CrI, credible interval; CRNMB, clinically-relevant non-major bleeding; DVT, deep vein thrombosis; eTHR, elective total hip replacement; eTKR, elective
total knee replacement; extd, extended; GI, gastrointestinal; ICH, intracranial hemorrhage; IPCD, intermittent pneumatic compressions device; LMWH, low molecular weight heparin;
PE, pulmonary embolism; SSB: surgical site bleeding; std, standard.
aNot in DVT NMA. Point estimate calculated based on the assumption that the relative effectiveness for the PE outcome compared to LMWH (std,std) + AES will be the same for the
DVT.
bNot in PE NMA. Point estimate calculated based on the assumption that the relative effectiveness for the DVT outcome compared to LMWH (std,std)+ AES will be the same for the
PE.
cSource: Jameson 2011 (Hauck et al., 2017).
dNot in PE network. Point estimate calculated based on the assumption that the relative effectiveness for the DVT outcome compared to LMWH (std,std)+ AES will be the same for the
PE.
eSource: Jameson 2012 (Arya et al., 2010).
Detailed calculations of the costs used in the analysis are
reported in Appendix P of NG89 and are summarized here
in Table 2 (National Institute for Health and Care Excellence,
2018).
Sensitivity Analyses (SAs)
A number of one-way deterministic sensitivity analyses were
undertaken to assess uncertainty in the model. These were as
follows: changing the cost-effectiveness threshold from £20,000
to £30,000 per QALY-gained (SA1), changing the discount
rate from 3.5% to 1.5% (SA2), changing the source of the
pharmacological prophylaxis duration from being based on the
RCTs to their licensed durations (SA3), changing the cohort
starting age to 40 years (SA4), changing the cohort body weight
from the NJR cohort mean weight to a distribution of body
weights calculated based on the NJR cohort BMI distribution
and average height for a UK male (1.75m) and female (1.62m;
SA5), increasing all intervention and event costs by 10% (SA6),
decreasing all costs by 10% (SA7), changing the timing of VTE
and MB events to be based on data from Warwick 2007 (SA8;
Warwick et al., 2007), using alternative rates of recurrence for
treated DVT and PE based on data from TA245 and TA354
manufacturer submissions (SA9; National Institute for Health
and Clinical Excellence, 2012; National Institute for Health
and Care Excellence, 2015), taking wastage into account when
calculating the costs of pharmacological prophylaxis (SA10) and
using alternative value for the risk of DVT when using LMWH
(std,std) followed by aspirin for the eTHR population which
is calculated using the odds ratio from Anderson 2013 for the
outcome proximal DVT rather than using the estimate from the
PE NMA results [SA11; (Anderson et al., 2013)].
Analysis Approach
The model was constructed in Microsoft Excel 2010 and was
evaluated by cohort simulation. Time dependency was built in
the long-term Markov part of the model by cross referencing
the cohorts age as a respective risk factor for mortality. Baseline
utility was also time dependent and was conditional on the
number of years after entry to the model.
Patients start in cycle 0 in the health state corresponding to the
end state of the decision tree part of the model. Patients moved
to the dead health state at the end of each cycle as defined by the
mortality transition probabilities from the life tables and CTEPH
mortality.
PTS and CTEPH incidence rates were converted into
transition probabilities for the respective cycle length (1 year in
the base case) before inputting into the Markov model. These
conversions were done using the following formulae:
Selected rate (r) =
− ln (1− P)
t
Where
P = probability of event over time t
t = time over which probability occurs(2 years)
Transition Probability (P) = 1− e−rt
Where
r = selected rate
t = cycle length (1 year)
Model Validation
The model was developed in consultation with the Committee;
model structure, inputs, and results were presented to and
discussed with the Committee for clinical validation and
interpretation.
The model was systematically checked by the health
economist undertaking the analysis (DD); this included inputting
null and extreme values and checking that results were plausible
given inputs. The model was peer reviewed by a second
experienced health economist from theNGC (DW); this included
systematic checking of the model calculations.
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TABLE 4 | Base case (dis-)utility values for events up to 90 days.
Mean (dis-)utility SE(a) Source
No event (baseline utility at 90 days) THR: 0.579 (BLU-THR) 0.057 PROMS 2014–2015 (Hunt, 2016)
TKR: 0.582 (BLU-TKR) 0.058 PROMS 2014–2015 (Hunt, 2016)
Asymptomatic DVT- Distal THR: 0.579 (BLU-THR) 0.057 PROMS 2014–2015 (Hunt, 2016)
Asymptomatic DVT- Proximal TKR: 0.582 (BLU-TKR) 0.058 PROMS 2014–2015 (Hunt, 2016)
Symptomatic DVT- Proximal −14% Cohen 2014 (Barco et al., 2016)
Symptomatic DVT- Distal (requiring treatment) −14% Assumption: equal to the disutility for symptomatic DVT-proximal
Symptomatic DVT- Distal (not requiring
treatment)
−7% Assumption: equal to the 50% of the disutility for symptomatic
DVT-proximal
Non-fatal PE −19% Cohen 2014 (Barco et al., 2016)
Warfarin treated DVT or PE −0.012 Marchetti 2001 (White et al., 2015) and Edoxaban TA354 (Cohoon
et al., 2015) company submission
Major bleeding (surgical site, GI with or without
intervention, other)
−32% Locadia 2004 (ISTH Steering Committee for World Thrombosis
Day, 2014)
ICH/acute stroke −65% Locadia 2004 (ISTH Steering Committee for World Thrombosis
Day, 2014)
Pre- aseptic revision surgery THR: 0.399 0.039 PROMS 2014–2015 (Hunt, 2016)
TKR: 0.329 0.033 PROMS 2014–2015 (Hunt, 2016)
Post-aseptic revision surgery THR: 0.538 0.054 PROMS 2014–2015 (Hunt, 2016)
TKR: 0.459 0.046 PROMS 2014–2015 (Hunt, 2016)
Post-reoperation for surgical site MB THR: 0.538 0.054 Assumed equal to post-aseptic revision
TKR: 0.459 0.046 Assumed equal to post-aseptic revision
CRNMB (including wound haematoma) −0.03 Sullivan 2011 (National Clinical Guideline Centre, 2010)
Surgical site infection −66% Baker 2013 (Roberts et al., 2013) for TKR, assumed the same for
THR
Post-infected revision/return to theater for
surgical site infection
−30% Baker 2013 (Roberts et al., 2013) for TKR, assumed the same for
THR
HIT −0.0712 Gould 1999 (Gould et al., 2012)
Post-HIT amputation −0.28 Beaudet 2014, T1D GL (Dahl et al., 2010)
Post-HIT thrombosis −16.5% Assumed average of PE and symptomatic proximal DVT
dis-utilities
Post-HIT MB −32% Assumed equal to Major bleeding (surgical site, GI with or without
intervention, other)
BLU, baseline utility; CRNMB, clinically-relevant non-major bleeding; GI, gastrointestinal; HIT, heparin-induced thrombocytopaenia; ICH, intracranial hemorrhage; MB, major bleeding;
PE, pulmonary embolism; SE, standard error; THR, total hip replacement; TKR, total knee replacement.
aWhere not reported; SE was calculated as 10% of the mean.
Estimation of Cost-Effectiveness
When there are more than 2 comparators, as in this analysis,
options must be ranked in order of increasing cost then
options ruled out by dominance or extended dominance before
calculating ICERs excluding these options. An option is said to
be dominated, and ruled out, if another intervention is less costly
and more effective. An option is said to be extendedly dominated
if a combination of 2 other options would prove to be less costly
and more effective.
It is also possible, for a particular cost-effectiveness threshold,
to re-express cost-effectiveness results in term of net monetary
benefit (NMB). This is calculated by multiplying the total
QALYs for a comparator by the threshold cost per QALY
value (for example, £20,000) and then subtracting the total
costs (formula below). The decision rule then applied is that
the comparator with the highest NMB, and hence the highest
incremental NMB (INMB) vs. the model comparator, is the
most cost-effective option at the specified threshold. That is
the option that provides the highest number of QALYs at an
acceptable cost.
Net Monetary Benefit (X) = (QALYs (X)× λ)− Costs(X)
Where : λ = threshold (£20, 000 per QALY gained)
Cost− effective if :Highest net benefit
Results are also presented graphically where the incremental costs
and incremental QALYs for each strategy compared to LMWH
(std,std)+AES are shown on the cost-effectiveness plane. Scatter
plots are also presented. We have also assessed the decision
uncertainty by calculating the probability of being the most
cost-effective option at the specified cost-effectiveness threshold.
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TABLE 5 | Base case (dis-)utility values for the Markov model health states (more than 90 days after surgery).
Mean (dis-)utility SE(a) Source duration
Post stroke (disabled) −10% Lunde 2013 (Board NE, 2017) 345
Stroke patients in Norway who had
ischaemic/haemorrhagic or TIA
lifetime
Mild to Moderate PTS −0.02 Lenert 1997 (Annemans et al., 2004) lifetime
Severe PTS −0.07 Lenert 1997 (Annemans et al., 2004) lifetime
CTEPH-Year 1 −26% Meads 2008 (Bischof et al., 2006) Operable or inoperable (3 months)
Recurrent/resistant (12 months)
CTEPH - Year 2- recurrent resistant
Chronic CTEPH
22% Meads 2008 (Bischof et al., 2006) Utility improvement after medical
treatment applied to CTEPH-Year 1
utility value
Chronic CTEPH utility applied lifetime
Post-HIT amputation −0.28 Beaudet 2014 (Dahl et al., 2010), T1D
GL (Bjorvatn and Kristiansen, 2005)
Lifetime
HIT, heparin-induced thrombocytopaenia; SE, standard error; T1D, Type 1 diabetes.
aWhere not reported; SE was calculated as 10% of the mean.
RESULTS
Base Case- eTHR
The results of the probabilistic base case analysis for the
eTHR population are presented in Table 7 and on the cost-
effectiveness plane as scatter plots in Figure 2A and as point
estimates in Figure 3A. These show that the most effective
option, with the highest mean QALYs-gained over lifetime
per person, was the prophylaxis strategy consisting of LMWH
(standard dose, standard duration) followed by aspirin (low
dose, extended duration; 10.293 discounted QALYs; 95% CI:
8.02 to 12.00). It was followed closely by LMWH (standard
dose, extended duration) + AES (10.288; 95% CI: 8.02
to 12.00). The highest cost option was aspirin (low dose,
standard duration), with mean discounted cost of £1,687
(95% CI: £157 to £4,039) per person. The lowest cost
prophylaxis strategy was AES, with mean discounted cost
per person of £299 (95% CI: £102 to £793) followed by
the strategy of LMWH (standard dose, standard duration)
followed by aspirin (low dose, extended duration) which
had a mean discounted cost of £311 (95% CI: £148 to
£1437).
Based on these results, the most cost-effective prophylaxis
strategy for eTHR was LMWH (standard dose, standard
duration) followed by aspirin (low dose, extended duration)
with mean INMB vs. LMWH (standard dose, standard duration)
+AES of £530 (95% CI: -£784 to £1,103). It also had the highest
probability of being the most cost-effective option (72%). Other
interventions which have a positive mean INMB compared
with LMWH (standard dose, standard duration) +AES were:
LMWH (standard dose, extended duration) + AES (INMB =
£36; 95% CI: -£745 to £484) and AES (INMB = £5; 95%
CI: -£2,106 to £781). However, compared to no prophylaxis,
all interventions except three (aspirin [low dose, standard
duration], foot pump and AES [above knee]) have positive
INMB.
Among the mechanical prophylaxis interventions; AES
seemed to be more cost-effective compared to IPCD and foot
pumps, ranking 3rd (95% CI: 1 to 14) when length was
unspecified. However, above-knee AES had negative INMB
compared to no prophylaxis and ranked in the 14th place (see
Table 7).
The DOACs (rivaroxaban, apixaban, and dabigatran) were
dominant compared to no prophylaxis but were dominated
by the model comparator (LMWH [standard dose, standard
duration] +AES). Of the three DOACs, rivaroxaban was
cost-effective compared to apixaban with an ICER of £12,242
per QALY-gained. Both rivaroxaban and apixaban were
dominant (more effective and less costly) compared to
dabigatran. The probability of being the most cost-effective
was higher for apixaban (2.24%) compared to rivaroxaban
(0.2%). However; there was more uncertainty around the
ranking of apixaban, with a probability of being the least
cost effective of 0.16% for apixaban compared to 0.08% for
rivaroxaban.
The disaggregated health outcomes and costs are presented
in Tables 8, 9. These show that the strategies that resulted in
the lowest number of VTE events are LMWH (standard dose,
standard duration) followed by aspirin (low dose, extended
duration) and LMWH (standard dose, extended duration) +
AES (8 [95%: 0 to 55] and 34 [95% CI: 5 to 116] per
1,000 persons; respectively). The highest number of VTE
events was, not surprisingly, seen with the no prophylaxis
strategy (491 per 1,000 (95% CI: 146 to 953). The number
of surgical site bleeding events was highest for fondaparinux+
AES (51 per 1,000 [95% CI: 8 to 187]) followed by dabigatran
with 44 per 1,000 [95% CI: 6 to 160]. Aspirin (low dose,
standard duration) was associated with the highest number
of PE, PTS, and CTEPH events (373, 60, and 11 per 1,000,
respectively).
The breakdown of costs for all prophylaxis strategies is in
line with the results for health outcomes. The cost of the
prophylaxis itself was highest for LMWH (standard duration,
extended duration)+ AES (£419 per person); driven by the
high administration and monitoring costs for an extended
duration.
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TABLE 6 | Total costs of each prophylaxis strategy in the eTHR and eTKR models.
Population and strategy Total costs of
pharmacological prophylaxis
(I)
Total costs of mechanical
prophylaxis (II)
Total intervention cost (I+II)
THR
LMWH (std,std) + AES £138 £31 £169
LMWH (std,extd)+ AES £387 £31 £419
Fondaparinux+ AES £83 £31 £115
Foot pump + AES £0 £91 £91
IPCD £0 £42 £42
AES (above knee) £0 £34 £34
Foot pump £0 £59 £59
AES £0 £31 £31
LMWH (std,std) £138 £0 £138
LMWH (std,extd) £387 £0 £387
Aspirin (std duration) £0.2 £0 £0.2
LMWH (std, std) + Aspirin (extd duration) £115 £0 £115
Dabigatran £80 £0 £80
Apixaban £59 £0 £59
Rivaroxaban £74 £0 £74
No prophylaxis £0 £0 £0
TKR
LMWH (std,std) + AES £111 £31 £142
Fondaparinux+ AES £97 £31 £128
Foot pump + AES £0 £91 £91
IPCD £0 £42 £42
Foot pump £0 £59 £59
AES £0 £31 £31
LMWH (std,std) £111 £0 £111
LMWH (std,extd) £355 £0 £355
Aspirin £0.5 £0 £0.5
Dabigatran £34 £0 £34
Apixaban £23 £0 £23
Rivaroxaban £25 £0 £25
No prophylaxis £0 £0 £0
AES, anti-embolism stockings; eTKR, elective total knee replacement; eTHR, elective total hip replacement; extd, extended; IPCD.
Base Case- eTKR
The results of the probabilistic base case analysis for the eTKR
population are presented in Table 7. Figure 2B presents the cost-
effectiveness plane with scatter plots while the point estimates
are presented in Figure 3B. These showed that the most effective
option, with the highest mean gain in QALYs over lifetime per
person, was foot pump (9.814 [95% CI: 7.86 to 11.58] discounted
QALYs gained). This was followed closely by aspirin (low dose,
standard duration) with a mean of 9.809 (95% CI: 7.86 to 11.58)
and LMWH (standard dose, standard duration) + AES with a
mean of 9.807 (95% CI: 7.86 to 11.58). The highest cost option
was fondaparinux+AES, with mean discounted costs £904 (95%
CI: £358 to £3,016). The lowest cost prophylaxis strategy was
aspirin (low dose, standard duration), with mean discounted
costs of £187 (95% CI: £118 to £304).
Based on these results, the most cost-effective prophylaxis
strategy, with the highest NMB, was foot pump with mean INMB
vs. LMWH (standard dose, standard duration) + AES of £353
(95% CI: -£101 to £665) followed by aspirin (low dose, standard
duration) with mean INMB of £281 (95% CI: -£195 to £703).
However, the results show considerable uncertainty where the
most cost-effective option (foot pump) rank having a 95% CI of 1
to 10 around the mean rank and a probability of being the most
cost-effective of only 18%. The only interventions with positive
INMB when compared with LMWH (std, std) + AES were foot
pump, aspirin, and the combined strategy of foot pump + AES.
Compared to no prophylaxis, though, all interventions had a
positive INMB except dabigatran.
Of the DOACs included in the model; rivaroxaban
dominated both apixaban and dabigatran. However, the
model comparator (LMWH [standard dose, standard
duration] + AES) was cost effective compared to rivaroxaban
(ICER: £7,686). The probability of being the most cost-
effective was higher for apixaban (44%) compared to
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FIGURE 2 | Scatter plots showing the probabilistic analysis results for (A) elective total hip replacement (eTHR) and (B) elective total knee replacement (eTKR)
populations.
rivaroxaban (18%). However; there was more uncertainty
around the ranking of apixaban, with a 5% probability
of it being the least cost effective compared to 0% for
rivaroxaban.
The disaggregated health outcomes and costs for all
prophylaxis strategies are presented in Tables 10, 11 These show
that rivaroxaban had the lowest number of VTE events (60 per
1,000 persons [95% CI: 14 to 211]). The number of surgical site
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FIGURE 3 | Cost effectiveness plane showing the mean incremental costs and QALYs compared to LMWH (standard dose, standard duration) + AES for (A) elective
total hip replacement (eTHR) and (B) elective total knee replacement (eTKR) populations.
bleeding events was highest for fondaparinux + AES (79 per
1,000 [95% CI: 2 to 411]) followed by rivaroxaban (16 per 1000
[95% CI: 1 to 67]). The “no prophylaxis” strategy was associated
with the highest number of PTS events (23 per 1,000 [7 to 81]),
Dabigatran had the highest number of PE events (51 per 1,000 [0
to 644]). The disaggregate costs were in line with the results for
health outcomes. The cost of the prophylaxis itself was highest for
LMWH (standard dose, extended duration) at £356 per person.
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Sensitivity Analyses
For the eTHR population, the results of the SAs show
that the most cost-effective option (LMWH [standard dose,
standard duration] followed by aspirin [low dose, extended
duration]) remained the same in all SAs except in SA4
where the mean age of the cohort was reduced to 40 years;
where it dropped to the second rank and LMWH (standard
dose, standard duration) + AES became the most cost
effective.
For the eTKR population, the optimal strategy (foot pump)
remained the same in all SAs. Dabigatran was the least cost
effective in all SAs.
DISCUSSION
To our knowledge, this is the most comprehensive and up-
to-date economic evaluation of VTE prophylaxis strategies to
be conducted from the English NHS and PSS perspective.
The results showed that, for eTHR, the most cost-effective
prophylaxis strategy is LMWH (standard dose, standard
duration) followed by aspirin (low dose, extended duration)
with mean INMB £530 (95% CI: -£784 to £1,103). It also
has the highest probability of being the most cost-effective
option (72%). Where parenteral options are not acceptable or
contraindicated; rivaroxaban would be the most cost-effective
prophylaxis option. Of the mechanical prophylaxis options
considered in the analysis; AES-based strategies appeared to
be the more cost-effective compared to IPCDs and foot
pumps.
For eTKR, foot pumps appeared to be the most cost-effective
option with mean INMB of £353 (95% CI: -£101 to £665), though
with a low (18%) probability of being the most cost-effective
option. It was followed closely by aspirin (low dose, standard
duration) with mean INMB of £281 (95% CI: -£195 to £703).
However, the results of the analysis in the eTKR population
were highly uncertain and should be interpreted with caution.
Indeed, the guideline committee did not feel that recommending
foot pump in this population would be appropriate if
pharmacological prophylaxis is a suitable option, as it is likely
to delay mobilization and, consequently, discharge. Instead, the
committee recommended aspirin (low dose, standard duration)
as first option. Foot pump/IPCD, however, was recommended
for those who have contraindications to pharmacological
prophylaxis.
The different results for the two populations can be explained
in terms of the differences in the baseline risk inputs used,
particularly the risk of symptomatic proximal DVT which also
has the highest probability of developing PTS in the longer
term. This risk was much higher in the eTHR population
which made the use of more costly, longer duration prophylaxis
options cost effective as the costs of these strategies are
offset by the savings achieved from avoiding these costly
events.
The relative cost effectiveness of the DOACs in this population
was similar to that in the eTHR population, with rivaroxaban
being the most cost effective of the three DOACs considered,
though the uncertainty was clearly higher than that seen in the
eTHR analysis, with very wide 95% CI around the ranking of
these interventions.
To our knowledge, this analysis is the first to include all
established interventions for primary prevention of hospital-
acquired VTE in eTHR and eTKR that are relevant to
clinical practice in the English NHS; including mechanical,
pharmacological, and combination prophylaxis. It is also the
first to account for some of the consequences of HIT, including
amputation, and to completely account for the consequences of
major bleeding including joint infections, wound haematoma
and return to theater. These improvements represent important
step forward in modeling VTE prophylaxis compared to
previously published models.
The model structure represented both the acute phase in
the immediate post-operative period as well as the long-term
phase to life-time time horizon; using a Markov model to
capture long-term consequences of VTE events including PTS
and CTEPH. It has been based on NMAs of the three main
outcomes DVT, PE, and MB. This is similar to the most
recently published UK analysis, which conducted NMAs of these
outcomes.
However, we have attempted to address the limitations of
the previously published models, including the NICE guideline
CG92 model, that were highlighted by the orthopedic surgery
community. For example, the lack of differentiation between
proximal and distal DVT was a major concern. We have
addressed this issue by differentiating between proximal and
distal DVT for both symptomatic and asymptomatic events,
allowing for different probabilities of progression from each
of these to clinical sequelae. We emphasized the fact that
asymptomatic DVT also does not have an impact on costs and
outcomes in the short term as it is not diagnosed in clinical
practice.
There was also previous criticism of the baseline risk used in
the model, which was based on data from the “no prophylaxis
arm” in historical trials from the 1970s. We have used baseline
risk estimates from observational cohort studies that used the
NJR data (Jameson et al., 2011, 2012). This is in line with the
NICE Reference Case specifications, which considers the most
appropriate source of baseline risk is large observational cohort
studies that describe the natural history of the disease/condition
of interest in the target population.
Overall, published economic evaluations that compared VTE
prophylaxis to no prophylaxis in eTHR and eTKR concluded
that prophylaxis was a cost-effective intervention (National
Colloborating Centre for Acute Care, 2007; National Clinical
Guideline Centre, 2010). The choice of an optimum prophylaxis
strategy, however, varied across studies and among countries.
This is partly explained by the difference in the range of
interventions included in each of these studies but also by
the differences in acquisition costs and sources of effectiveness
evidence. Our analysis is concordant with the conclusion reached
by Brockbank and Wolowacz (2017) that the difference between
the included interventions in terms of QALYs-gained is very
small and the results are likely to be more sensitive to differences
in costs.
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The results also showed that out of the DOACs considered;
rivaroxaban is likely to be the most cost-effective. This was
seen particularly in the eTHR population where rivaroxaban
dominated dabigatran and was cost-effective compared to
apixaban with an ICER of £12,242 per QALY-gained. This finding
was in line with the results of NICE TA170, where rivaroxaban
was found to dominate dabigatran (National Institute for Health
and Clinical Excellence, 2009).
A recent analysis funded by the NIHR found that rivaroxaban
dominated dabigatran and was cost-effective compared to
apixaban with an ICER of £114 per QALY gained (Sterne
et al., 2016). TA245 also found that dabigatran was dominated,
apixaban was extendedly dominated and rivaroxaban had an
ICER of £22,123 per QALY-gained compared to fondaparinux
(National Institute for Health and Clinical Excellence, 2012).
In eTKR, rivaroxaban dominated both apixaban and
dabigatran. This was in line with the results of the economic
models assessed as part of NICE TA170 and TA245 and a more
recent analysis funded by the NIHR (National Institute for
Health and Clinical Excellence, 2009, 2012; Sterne et al., 2016).
However; our analysis showed that LMWH in combination
with AES, which is the most commonly prescribed prophylaxis
strategy in the UK, is more cost effective than the DOACs.
This is in accordance with Kapoor et al. (2010) who concluded
that fondaparinux and extended duration LMWH can be cost-
effective strategies. However, in our analysis, fondaparinux was
not considered cost effective due to the high risk of bleeding and
the costs associated with it.
Despite all our efforts, though, the results of this economic
analysis for the eTKR population remain uncertain. This is
largely due to the uncertainty and imprecision of theNMA results
that informed it; which resulted from the sparse nature of the
networks for the PE and MB outcomes in this population. This
made it difficult to precisely estimate the relative effectiveness
of the interventions. The resulting imprecise estimates of cost
effectiveness preclude defining a clear ranking of the included
interventions in terms of their cost-effectiveness. However, this
is a reflection of the state of the collective body of evidence in this
clinical area; which calls for future research to focus on producing
better quality evidence that assesses the relative efficacy of VTE
prophylaxis in eTKR.
The results of this analysis have also been largely based on
epidemiological and cost data specific to England including the
cohort characteristics which were based on data from the NJR.
Additionally, the interventions included in the analysis were
true to current clinical practice. Furthermore, this analysis has
been undertaken from the NHS and PSS perspective. These
factors may limit the generalisability to other populations and
settings. However, the relative efficacy estimates were based on
comprehensive SR and NMAs that did not restrict the inclusion
of studies to specific countries.
Nevertheless, this economic evaluation is the most
comprehensive and up-to-date assessment of the cost
effectiveness of VTE prophylaxis strategies in major orthopedic
surgeries. Its results informed the NICE guideline committee’s
recommendation which defined the VTE prophylaxis options to
be used in eTHR and eTKR in the English NHS hospitals.
CONCLUSIONS
To conclude, in people undergoing elective total hip and elective
total knee replacement surgeries, VTE prophylaxis appears
to be cost effective compared to no prophylaxis. A strategy
consisting of LMWH for 10 days followed by aspirin for 28 days
was the most cost-effective for elective total hip replacement.
For elective total knee replacement, the results were highly
uncertain. Foot pump appeared to be the most cost-effective
strategy followed closely by aspirin (low dose). However, these
results should be interpreted with caution within the context of
current clinical practice and combined with other considerations
including patient preferences to inform prescribing decisions.
Future research should focus on assessing cost-effectiveness of
VTE prophylaxis in the eTKR population.
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